SCHEMBL3155607

SCHEMBL3155607

CCOC(=O)c1cnc(N2CCN(C(=O)OC(C)(C)C)CC2)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGA O60502 2/20 0.52
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
GPR119 Q8TDV5 4/20 0.46
HRH3 Q9Y5N1 2/20 0.45
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45
SKP2 Q13309 1/20 0.45
MAPT P10636 2/20 0.44
ADORA1 P30542 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2575502 0.87 HRH3 (0.58) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL14164267 0.87 OGA (0.45) OGAGPR119HRH3CKS1BSKP1
SCHEMBL8083829 0.87 OGA (0.44) OGAGPR119HRH3MAPTADORA1
SCHEMBL2828808 0.86 HDAC3 (0.48) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3787851 0.84 OGA (0.57) OGAHDAC3HDAC4HDAC1HDAC7
SCHEMBL16501434 0.84 HDAC3 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2146303 0.84 SCD (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL3145554 0.84 OGA (0.51) OGAHDAC3HDAC4HDAC1HDAC7
SCHEMBL13261644 0.83 HRH3 (0.57) OGAHDAC3HDAC4HDAC1HDAC7
SCHEMBL2828526 0.83 HDAC3 (0.50) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398130-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2025-08-26 US disclosed
US-12187741-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2025-01-07 US disclosed
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2023-04-20 US disclosed
US-11591327-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2023-02-28 US disclosed
CN-109071526-B Acid addition salts of piperazine derivatives 阿森纽荣股份公司 2023-02-28 CN disclosed
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors REGENACY PHARMACEUTICALS, LLC (US) 2023-01-03 US disclosed
US-20220411440-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-12-29 US disclosed
CN-107108601-B Glycosidase inhibitors 阿森纽荣股份公司 2021-08-20 CN disclosed
EP-3186243-B1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-21 EP disclosed
US-11046712-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2021-06-29 US disclosed
EP-2398796-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Canada Inc. (CA) 2011-12-28 EP disclosed
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC. (CA) 2011-12-08 US disclosed
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC. (CA) 2011-12-08 US disclosed
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK CANADA INC. (CA) 2011-12-08 US disclosed
WO-2010094126-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-08-26 WO disclosed
EP-1765816-B1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS GRUENENTHAL GMBH (DE) 2010-03-10 EP disclosed
US-7300939-B2 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-11-27 US disclosed
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1765816-A1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS Grünenthal GmbH (DE) 2007-03-28 EP disclosed
WO-2006002981-A1 SUBSTITUTED 1-PROPIOLYLPIPERAZINES HAVING AN AFFINITY FOR THE MGLUR5 RECEPTOR IN ORDER TO TREAT PAINFUL CONDITIONS Grünenthal GmbH (DE) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 OGA 452/4885HDAC3 782/4885HDAC4 617/4885
US-20220411440-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 OGA 77/4885HDAC3 1212/4885HDAC4 1259/4885
US-11591327-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 OGA 452/4885HDAC3 782/4885HDAC4 617/4885
US-12187741-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 OGA 77/4885HDAC3 1212/4885HDAC4 1259/4885
US-11542242-B2 Substituted piperazines as selective HDAC1,2 inhibitors HDAC1, HDAC2, HDAC11 OGA 3649/4885HDAC3 8/4885HDAC4 6/4885
US-12398130-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 OGA 452/4885HDAC3 782/4885HDAC4 617/4885
US-20110301143-A1 HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, COASY OGA 1523/4885HDAC3 447/4885HDAC4 1172/4885
US-20070112011-A1 Substituted 1-propiolylpiperazine compounds, their preparation and use GRM5, GRIK5, GRM1 OGA 4512/4885HDAC3 1493/4885HDAC4 3304/4885
US-11046712-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 OGA 77/4885HDAC3 1212/4885HDAC4 1259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.